Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Yukio Kondo, Albert Oriol, Lionel Karlin et al.|The Lancet Haematology|2019

Cited by 247